Clinical Trial Update: Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating camrelizumab with albumin-bound paclitaxel and platinum as neoadjuvant therapy for resectable non-small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• Camrelizumab (camrelizumab)
• Platinum (Platinum-based chemotherapy)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Non-small-cell Lung Cancer (NSCLC) | Phase 2 | Status: UNKNOWN